

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT:	CAGNONI <i>et al.</i>	}	EXAMINER:
INT'L APP'L NO.	PCT/US2005/013708		ART UNIT:
INT'L FILING DATE:	APRIL 22, 2005		CONFIRMATION NO.:
U.S. SERIAL NO.:	10/598,869		1638
TITLE:	COADMINISTRATION OF RADIATION, EFAPROXIRAL SODIUM, AND SUPPLEMENTAL OXYGEN FOR THE TREATMENT OF CANCER		

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

INFORMATION DISCLOSURE STATEMENT

Applicant calls the Examiner's attention to the patents and publications listed on the attached Form PTO-1449, copies of required documents enclosed, which may be material to examination of the above identified application.

TIME OF TRANSMITTAL

This Information Disclosure Statement is being filed under 37 CFR § 1.97(b). This Statement is filed within at least one of the following time periods:


- (a) within three months of the filing date of a national application (other than a CPA under 37 CFR § 1.53(d));
- (b) within three months of the date of entry of the national stage as set forth in 37 CFR § 1.491 in an international application;
- (c) before the mailing of a first Office Action of the merits; or
- (d) before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR § 1.114.

No fee is believed to be due in this instance. However, the undersigned hereby authorizes the charging of any fees created by the filing of this document to Deposit Account No. 19-5117.

The filing of this Information Disclosure Statement shall not be construed as an admission against interest in any manner. This listed patents and publications are believed of interest herein and consideration and citation of as interest by Examiner is respectfully requested.

Respectfully submitted,

Date: Nov. 28, 2006



Mary Breen Smith, #43,512
Swanson & Bratschun, L.L.C.
1745 Shea Center Drive, Suite 330
Highlands Ranch, Colorado 80129
Telephone: (303) 268-0066
Facsimile: (303) 268-0065

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE List of Information Cited by Applicant Page 2 of 3	ATTY. DOCKET NO. ALL.07/PCT-US	SERIAL NO. 10/598,869
	APPLICANT CAGNONI	
	FILING DATE	GROUP

U.S. PATENT DOCUMENTS							
EXAM. INITIAL		DOCUMENT NUMBER	DATE	NAME	CLS	SUB- CLS	FILE DATE
	AA	5,049,695	09/17/91	Abraham et al.			
	AB	5,122,539	06/16/92	Abraham et al.			
	AC	5,248,785	09/28/93	Abraham et al.			
	AD	5,250,701	10/05/93	Abraham, et al.			
	AL	5,290,803	03/01/94	Abraham et al.			
	AL	5,382,680	01/17/95	Abraham, et al.			
	AC	5,432,191	07/11/95	Abraham et al.			
	AH	5,525,630	06/11/96	Hoffman			
	AL	5,591,892	01/07/97	Abraham et al.			
	AJ	5,648,375	07/15/97	Abraham			
	AK	5,661,182	08/26/97	Abraham et al.			
	AL	5,665,382	09/09/97	Grinstaff			
	AM	5,677,330	10/14/97	Abraham et al.			
	AN	5,705,521	01/06/98	Abraham			
	AB	5,731,454	03/24/98	Abraham et al.			
	AE	5,827,888	10/27/98	Abraham et al.			
	AQ	5,927,283	07/27/99	Abraham et al.			
	AR	6,486,342	11/26/02	Abraham et al.			
	AS	US 2003-0232887	12/18/03	Johnson et al.			
	AT						

FOREIGN PATENT DOCUMENTS							
EXAM. INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLS	SUB CLS	TRANS ?
	AU	24 32 560	01/22/1976	Germany			
	AV	WO 97/34594	09/25/1997	WO			
	AW	WO 01/14316	03/01/2001	WO			
	AX	WO 03/086324	10/23/2003	WO			
	AY	WO 03/092700	11/13/2003	WO			

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)	
AZ	Abraham et al. (1992) Biochemistry 31:9141-9149
AAC	Abraham et al. (1998) Med. Chem. Res. 8:478-486
AAD	Amorino et al. (2001) Radiation Research 156:294-300
EXAMINER	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE List of Information Cited by Applicant Page 3 of 3	ATTY. DOCKET NO. ALL.07/PCT-US	SERIAL NO. 10/598,869
	APPLICANT CAGNONI	
	FILING DATE	GROUP

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
BA	Chang et al. (2003) The Oncologist. 8:398	
BB	Grella et al. (2000) Journal Med. Chem. 43:4726-4737	
BC	Kavanagh et al. (2001) Int. J. Radiation Oncology Biol. Phys. 49:1133	
BD	Muguruma et al. (July 1999) LC-GC International, 432-436	
BE	Pagel et al. (1998) Journal of Pharmacology and Experimental Therapeutics 285:1	
BF	Papassotiriou et al. (1998) Experimental Hematology 26:922-926	
BL	Randad et al. (1991) J. Med. Chem. 34:752	
BH	Rockwell and Kelley (1998) Rad. Oncol. Invest. 6:199	
BL	Rowinsky (1999) Oncology 10:61-70	
BT	Safo et al. (2001) Protein Science 10:951	
BK	Sarraf-Yazdi et al. (1999) Brain Research 826:172-180	
BL	Steffen (1998) Oxygen Transport to Tissue XX 454:653	
BM	Steffen et al. (2003) Advances in Experimental Medicine and Biology, 530:249	
BN	Teicher et al. (1996) Drug Dev. Res. 38(1):1	
BD	Teicher et al. (1998) Cancer Chemother. Pharmacol. 42:24	
BE	Wahr et al. (2001) Anesth. Analg 95:615	
BD	Watson et al. (1997) Stroke 28:1624	
EW	Wireko et al. (1991) Journal of Medicinal Chemistry 34:758-767	
BS		
BT		
BU		
BV		
BW		
EXAMINER		DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.		

S:\Client\Folders\Allios\07\PTC\US\SIDS.doc